The expression of Bcl-x is downregulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage

Blood. 1997 May 1;89(9):3199-204.

Abstract

Expression of the apoptosis inhibitory protein Bcl-x was studied in CD34+ hematopoietic precursor cells and in the promyelocytic leukemia cell line HL-60. The enriched population of CD34+ cells (more than 95%) was cultured in the presence of stem cell factor, interleukin-3 (IL-3), IL-6, and either granulocyte colony-stimulating factor or macrophage colony-stimulating factor to achieve granulocyte or monocyte/macrophage differentiation, respectively. The expression of Bcl-x increased in the early stages of both differentiation pathways. However, by day 21 of culture mature granulocytes were Bcl-x-negative, whereas monocytes/macrophages either maintained or increased the expression of Bcl-x. The pattern of Bcl-x expression in the differentiated CD34+ cells was similar to that observed in HL-60 cells differentiated along the granulocyte lineage (induced by incubation with retinoic acid), or along the monocyte/macrophage lineage (induced by incubation with phorbol diester). The bcl-x transcript predominant in HL-60 and CD34+ cells differentiated into monocytes/macrophages was bcl-xL. Although little is yet known regarding the functional significance of Bcl-x within the granulomonocytic compartment, marked changes in the pattern of its expression, as observed during granulomonocytic differentiation of HL-60 and CD34+ cells, are likely to alter the life span of mature granulocytes and monocytes/macrophages.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / analysis
  • Antigens, CD34 / analysis
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Colony-Stimulating Factors / pharmacology*
  • Flow Cytometry
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Granulocytes / cytology*
  • HL-60 Cells
  • Hematopoietic Stem Cells / cytology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / physiology*
  • Humans
  • Interleukin-3 / pharmacology
  • Interleukin-6 / pharmacology
  • Macrophage Colony-Stimulating Factor / pharmacology
  • Macrophages / cytology*
  • Monocytes / cytology*
  • Proto-Oncogene Proteins / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • RNA, Messenger / biosynthesis
  • Stem Cell Factor / pharmacology
  • Transcription, Genetic / drug effects*
  • bcl-X Protein

Substances

  • Antigens, CD
  • Antigens, CD34
  • BCL2L1 protein, human
  • Colony-Stimulating Factors
  • Interleukin-3
  • Interleukin-6
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Messenger
  • Stem Cell Factor
  • bcl-X Protein
  • Granulocyte Colony-Stimulating Factor
  • Macrophage Colony-Stimulating Factor